Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma
We demonstrated the advantage of IO-TKI combination therapy compared to TKI monotherapy in real-world clinical settings. However, in IMDC favorable patients PFS and OS did not significantly differ to TKI monotherapy. This may indicate the need for caution when selecting treatment options for IMDC favorable-risk patients.
Authors
- Takemura Ayana
- Keita Tamura (ORCID: https://orcid.org/0000-0002-4305-7328)
- Kyohei Watanabe (ORCID: https://orcid.org/0000-0002-8242-8611)
- YUTO MATSUSHITA
- Atsushi Otsuka (ORCID: https://orcid.org/0000-0001-6472-0988)
- Gaku Ishikawa
- Teruo Inamoto (ORCID: https://orcid.org/0000-0002-1351-1315)
- Daisuke Motoyama (ORCID: https://orcid.org/0000-0002-5315-3874)
- Hiromitsu Watanabe (ORCID: https://orcid.org/0000-0001-5186-7139)
- Y. Tsuchiya (ORCID: https://orcid.org/0000-0002-6481-8480)
- Shunsuke Watanabe (ORCID: https://orcid.org/0000-0001-7803-396X)
- SANO ASUKA
Institutions
- Hamamatsu University School of Medicine (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17426
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00